The following is an excerpt from Becker's Hospital Review.
Moderna and Merck entered an agreement Oct. 12 to develop, manufacture and sell personalized cancer vaccine candidates.
The two drugmakers have been collaborators since 2016, but under the amended agreement, Merck will pay Moderna $250 million before the end of 2022's third quarter. They will equally share costs and profits, according to a news release.
Moderna's vaccine candidate mRNA-4157/V940 is currently being tested in a phase 2 trial alongside Merck's immunotherapy treatment Keytruda, which is approved to treat multiple cancers.
Cancer vaccines tailored to one person, also called neoantigen vaccines, have previously shown positive results in small, preliminary trials, but the commercial market is about five years away from seeing them approved, researchers predict.
Read more here.
The Lemonade Mermaid Store
Unique gifts for Land or Sea Mermaids, Mer-pets and Little Mermaids!
Left: Our signature Blue Fins Earrings